Abstract 273P
Background
The nuclear factor-κB (NF-κB) pathway has been considered an essential and tightly regulated signaling cascade that mediates the development, activation, and survival of lymphocytes for regulated immune responses. Moreover, many of the oncogenic mediators involved in the pathology of lymphoma are regulated by NF-κB. Abnormal NF-κB activation occurs during many pathological conditions. A20 (intracellular ubiquitin-editing protein) is a negative feedback regulator of NF-κB signaling. A20 was identified as a MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) substrate, and MALT1 can cleave A20 to impair its NF-κB inhibitory function.
Methods
This study was carried out on 100 subjects classified into the following groups: Group I: included 80 patients with Non-Hodgkin Lymphoma (NHL). Group II: Included 20 ages and sex matched healthy individuals as a control group. All participants were subjected to full history taking and clinical examination. All NHL cases were subjected to abdominal ultrasound & CT-scan for abdomen and metastatic work up: chest x-ray and bone scan. Blood sample were taken for CBC, ESR, Serum LDH and β2 microglobulin (β2M) levels and detection of MALT1, A20 and NF-κB genes expression in cDNA samples extracted from RNA samples by reverse transcription by using real time PCR using SYBR Green technique.
Results
There was significant statistical increased expression of MALT1 and NF-κB and significant statistical decreased expression of A20 in NHL cases when compared with control. In NHL patients there was significant statistical decreased expression of MALT1, A20 and NF-κBin (HCV +ve) NHL cases when compared with controls and there was significant statistical increased expression of MALT1 and NF-κBand significant statistical decreased expression of A20 in (HCV-ve) NHL cases when compared with controls.
Conclusions
MALT1- A20 and NF-κB have specific expression pattern in patients with Non Hodgkin Lymphomas.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia university.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract